Eurofins Clinical Testing Lux Sarl, a subsidiary of Eurofins Scientific, has agreed to acquire Vietnam-based Genetic Testing Service (Gentis) for an undisclosed sum.

Gentis offers specialised DNA testing services, including obstetrical genetics, genealogical DNA tests, oncology and Covid-19 testing services.

Last year, the company had reported revenue of up to €10m.

The acquisition of Gentis will enable Eurofins to expand its presence in Asia, in addition to complementing its global network of clinical diagnostics laboratories focused on specialised and advanced genetic testing.

Eurofins CEO Dr Gilles Martin said: “I am looking forward to welcoming Gentis and its highly qualified and dedicated team to the Eurofins network.

“This acquisition demonstrates our commitment to provide testing solutions to meet critical health, wellness and genetic challenges. It also supports our growth strategies in both Asia and advanced specialised clinical diagnostics.”

According to Eurofins, specialised genetic testing is a significant growth opportunity, as it helps in the detection of cancers, chromosomal disorders during pregnancy and the prevention of genetic disorders.

Gentis is anticipated to support Eurofins’ strategy to expand further into these markets, as well as expand its presence in South East Asia.

In December last year, Eurofins Scientific agreed to acquire Japan-based testing services provider Genetic Lab (G Lab) from Transgenic for an undisclosed sum.

G Lab is engaged in delivering molecular biology based testing for diagnostics, biomarker development and drug discovery.

Eurofins offers testing and laboratory services for genomics, discovery pharmacology, forensics, biopharma contract development and manufacturing, advanced material sciences and clinical studies.